Christine Fox - Nov 20, 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
EVP, Head of U.S. Commercial
Signature
/s/ Dov Bergwerk as attorney-in-fact for Christine Fox
Stock symbol
TEVA
Transactions as of
Nov 20, 2025
Transactions value $
-$699,523
Form type
4
Date filed
11/24/2025, 04:03 PM
Previous filing
Nov 18, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Fox Christine EVP, Head of U.S. Commercial C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL /s/ Dov Bergwerk as attorney-in-fact for Christine Fox 2025-11-24 0001998173

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +63.5K +223.69% 91.9K Nov 20, 2025 Direct F1, F2
transaction TEVA Ordinary Shares Sale -$700K -28.2K -30.73% $24.78 63.6K Nov 20, 2025 Direct F1, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -63.5K -33.33% $0.00 127K Nov 20, 2025 Ordinary Shares 63.5K Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.
F4 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
F5 Restricted share units were granted on November 20, 2023, with 63,492 vested on each of November 20, 2024 and November 20, 2025, and 63,492 vesting on each of November 20, 2026 and November 20, 2027.